Related Experiment Videos
Soluble HLA class I and beta-2-microglobulin plasma concentrations during interferon treatment of chronic myelogenous
K Hillebrand1, T Moritz, U Westhoff
1Institute of Immunology, University Hospital of Essen, Medical School, Germany.
Insights
Interferon treatment for chronic myelogenous leukemia (CML) initially decreased soluble HLA class I molecules (sHLA-ABC). Levels then rose before returning to baseline, showing no difference between IFN-alpha and combination therapy.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Soluble human leukocyte antigen class I molecules (sHLA-ABC) play a role in immune regulation.
- Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome (Ph1).
- Interferon (IFN) therapy has been used in CML treatment.
Purpose of the Study:
- To investigate the dynamic changes in plasma sHLA-ABC levels during interferon treatment in CML patients.
- To compare the effects of IFN-alpha and combination IFN-alpha plus IFN-gamma therapy on sHLA-ABC levels.
Main Methods:
- Plasma sHLA-ABC levels were measured using enzyme-linked immunosorbent assay (ELISA) in 13 CML patients.
- Measurements were taken at multiple time points before, during, and after interferon treatment.
- Beta-2-microglobulin levels were also assessed and correlated with sHLA-ABC.
Main Results:
- Baseline sHLA-ABC levels were within the normal range.
- An initial transient decrease in sHLA-ABC was observed within 2-8 hours of IFN initiation.
- sHLA-ABC levels subsequently increased, peaking within 2-5 weeks, and then returned to near baseline levels within 2-4 months.
- No significant difference in sHLA-ABC response was noted between IFN-alpha and combination therapy.
- A positive correlation was found between sHLA-ABC concentrations and beta-2-microglobulin levels (r = 0.48).
Conclusions:
- Interferon treatment induces dynamic changes in sHLA-ABC levels in CML patients.
- The observed pattern suggests a complex interaction between IFN therapy and immune molecule expression.
- Beta-2-microglobulin may serve as a related biomarker for sHLA-ABC modulation in CML.
Abstract:
Soluble class I molecules (sHLA-ABC) were measured by an enzyme-linked immunosorbent assay (ELISA) in plasma samples of 13 patients with chronic-phase Ph1-positive chronic myelogenous leukemia (CML). The patients were treated once daily with interferon (IFN) s.c. at a dosage of 4 x 10(6) IU/m2 IFN-alpha-2b or in combination with 50 micrograms IFN-gamma. Measurements were performed before 2, 4, 6, 8, 24, 48, and 72 h after the start of treatment and thereafter every 2-4 weeks. Baseline sHLA-ABC levels were within normal limits (mean 22.1 +/- 8.8 mg/l). An initial decrease of sHLA-ABC (mean 3.2 +/- 2.7 mg/l) was seen in all patients during the first 2-8 h of IFN treatment. Thereafter, sHLA-ABC levels increased steadily reaching maximum values within 2-5 weeks. The overall increase was 12.7 +/- 12.4 mg/l. During the following 2-4 months of IFN treatment sHLA-ABC decreased to near baseline levels in 12 of 13 patients. No difference was detected between IFN-alpha and IFN-alpha plus IFN-gamma treatment. beta 2-Microglobulin values were measured in 8 patients and were found to be correlated to sHLA-ABC concentrations (r = 0.48).